Tag Archives: Alzheimer’s

FDA Just Fast-Tracked a Vaccine for Alzheimer’s

The U.S. Food and Drug Administration granted fast track designation to UB-311, a vaccine for Alzheimer’s disease made by biotechnology company Vaxxinity.1 The shot is an anti-amyloid beta immunotherapeutic vaccine that reportedly treats Alzheimer’s disease by targeting aggregated amyloid beta in the brain.2 Aside from the potential problems that can arise when a vaccine is… Read More »

‘I don’t like it:’ Biogen’s latest Alzheimer’s ad rouses fresh Aduhelm concerns—and some defense

Maybe you occasionally forget appointments or social events, or lose your train of thought in a conversation. Maybe you’re feeling depressed or overwhelmed when making a decision.  According to a online symptoms quiz from Biogen and Japanese partner Eisai, those are just a handful of signs of mild cognitive impairment (MCI), an early indication of… Read More »

How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

Advertisement Continue reading the main story Supported by Continue reading the main story How an Unproven Alzheimer’s Drug Got Approved Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab. The F.D.A. conducted an internal inquiry this year after allegations were… Read More »

High-profile Biogen ads hype early Alzheimer’s detection as hospitals reject Aduhelm prescriptions

How do you sell an Alzheimer’s treatment mired in controversy over its disputed benefits? Biogen is turning to “Jim and Jane” for help.  That’s the couple grappling with the memory-robbing disease that Biogen and Japanese partner Eisai have placed at the center of their new marketing campaign, “It’s Time We Know.” The campaign is designed… Read More »

In cost-saving move, Medicare could limit patient access to Alzheimer’s treatment

Medicare might restrict patient access to Alzheimer’s treatment priced at $ 56,000 for a year’s supply to soften the financial blow to the federal insurance program’s budget. “Whether or not that drug will be covered by Medicare and Medicaid is is an outstanding question, something that HHS will have to deal with,” said Health and… Read More »

Biogen CEO says $56,000 annually for Alzheimer’s drug is ‘fair,’ promises not to hike price for at least 4 years

Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $ 56,000 per year for the company’s FDA-approved Alzheimer’s disease drug aducanumab is “fair.” That being said, the Massachusetts-based biotech company has vowed to not increase the price of the medication, which is marketed under the name Aduhelm, for the next four… Read More »